Sunday, July 6, 2008

Fwd: The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 4, 2008 at 3:25 AM
Subject: The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer.
To: mesothelioma77@gmail.com


[1]Int J Colorectal Dis. 2008 Jul 2;
Rajaganeshan R, Prasad R, Guillou PJ, Poston G, Scott N, Jayne DG

GOALS: Tumour hypoxia has been shown to be a predictor of early distant relapse in node-negative breast and cervical cancer. The purpose of the present study was to determine the role of hypoxia in predicting patients who are at high risk of disease recurrence in Dukes B colorectal cancers. MATERIALS AND METHODS: Archival tissue was retrieved from 52 patients who had undergone surgical resection for primary colorectal cancer. Tissue micro-arrays were constructed using tissue from the margin and the centre of the tumour. Hypoxia markers hypoxia-inducible factor (Hif)-1alpha, vascular endothelial growth factor (VEGF), carbonic anhydrase (CA)-9 and glucose transporter (Glut)-1 were visualised using immunohistochemical detection and quantified using semi-quantitative analysis of the digitised images. Clinical details and outcome data were retrieved by case note review and collated with hypoxia markers data in a statistical database. RESULTS: Primary colorectal cancers with a high Hif-1alpha expression tended to have a significantly worse disease-free survival (log rank p

___
Source: http://www.hubmed.org/display.cgi?uids=18594846
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Peregrine initiates dosing in Phase II lung cancer trial (Pharmaceutical Business Review)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 4, 2008 at 3:26 AM
Subject: Peregrine initiates dosing in Phase II lung cancer trial (Pharmaceutical Business Review)
To: mesothelioma77@gmail.com


Peregrine Pharmaceuticals has initiated patient screening and dosing in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer.

Wed, 02 Jul 2008 00:46:15 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13c60qv4a/*http%3A//www.pharmaceutical-business-review.com/article_news.asp?guid=13036690-82A5-46D6-B3A9-E429F7312777
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: 'Celebrate Hope' for lung cancer research at Capital Brewery (The Capital Times)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 4, 2008 at 3:26 AM
Subject: 'Celebrate Hope' for lung cancer research at Capital Brewery (The Capital Times)
To: mesothelioma77@gmail.com


A new event to support national lung cancer research will be held at Middleton's Capital Brewery in August. Celebrate Hope will benefit the Creating Hope Lung Cancer Campaign, which provides funds for lung cancer research at University of Wisconsin's Paul P. Carbone Comprehensive Cancer Center in Madison. The event -- Sunday, Aug. 10 from 2 p.m. to 7 p.m. -- will be hosted by the Credit Union ...

Tue, 01 Jul 2008 23:44:50 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=1178gtr83/*http%3A//madison.com/tct/news//294193
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc